Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Swiss pharma giant Novartis has picked up US Food and Drug Administration approval for a label update for Cosentyx (secukinumab). 31 January 2020
Biotechnology
Shares of US biotech giant Amgen were down 2.5% at $220.56 in after-hours trading on Thursday, after the company announced fourth-quarter and full-year 2019 financial results year. 31 January 2020
Biotechnology
UK-based Exscientia has offered some compelling evidence to prove its claim to be the leading AI-driven drug discovery company. 30 January 2020
Biotechnology
Dutch rare disease specialist ProQR Therapeutics (Nasdaq: PRQR) has been given Rare Pediatric Disease (RPD) designation for its candidate QR-421a. 30 January 2020
Biotechnology
US biotech Alexion Pharmaceuticals today announced financial results for the fourth quarter and full year of 2019 which were above expectations, but its full year sales forecast missed, sending the firm’s shares down nearly 4.7% to $101.85 in mid-morning trading. 30 January 2020
Biotechnology
US biotech major Biogen today reported full year and fourth quarter 2019 financial results which beat expectations and saw the firm’s shares up 2.15% at $288.60 in pre-market trading. 30 January 2020
Biotechnology
Swiss pharma giant Roche is succeeding in replacing revenues lost to biosimilar competition to its older drugs. 30 January 2020
Biotechnology
Shares of USA-based Inovio Pharmaceuticals were up more than 15% at $4.74 pre-market today, as the company revealed it is collaborating with Beijing Advaccine Biotechnology Co to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date. 30 January 2020
Biotechnology
Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. 30 January 2020
Biotechnology
The European Commission (EC) has approved a second indication in prostate cancer for Erleada (apalutamide), from the Johnson & Johnson unit Janssen. 29 January 2020
Biotechnology
Shanghai, China-based WuXi Biologics says it has increased efforts in enabling the development of multiple neutralizing antibodies for the current outbreak of a novel coronavirus (2019-nCoV), centered in Wuhan, China. 29 January 2020
Biotechnology
The US Food and Drug Administation (FDA) has underlined its support for the field of gene therapies as it announces the release of guidelines for drug developers and manufacturers. 29 January 2020
Biotechnology
Gilead Sciences’ subsidiary Kite today announced that its Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), has been fully validated and is now under evaluation by the European Medicines Agency. 29 January 2020
Biotechnology
The Roche majority-owned drugmaker Chugai has settled with the UK Research and Innovation agency and associated charity LifeArc, nearly three years after the lawsuit was filed against the company. 29 January 2020
Biotechnology
A reverse merger between BioPharmX and Timber Pharmaceuticals has been agreed, giving the latter a quick and easy route to public markets to help develop its novel dermatology candidates. 29 January 2020
Biotechnology
Eli Lilly and its partner Incyte have announced positive Phase III results on baricitinib’s use alongside topical corticosteroids in moderate to severe atopic dermatitis (AD) that is not controlled with cyclosporine. 28 January 2020
Biotechnology
In November last year, Ireland-incorporated biotech Alkermes submitted a New Drug Application (NDA) for ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and bipolar I disorder, and today announced that the US Food and Drug Administration has accepted the NDA for review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 15, 2020 28 January 2020
Biotechnology
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) for a children’s eczema indication. 28 January 2020
Biotechnology
Japanese drugmaker Otsuka Pharmaceutical has announced positive preliminary results from two, Phase II/III trials for fremanezumab as a prophylactic migraine drug. 28 January 2020
Biotechnology
The last twelve months have offered a wild ride for investors in Boston’s Acceleron Pharma. 28 January 2020
All news
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze